Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome
Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, howeve...
Saved in:
Published in | Clinical science (1979) Vol. 125; no. 5; pp. 257 - 264 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.09.2013
|
Subjects | |
Online Access | Get full text |
ISSN | 0143-5221 1470-8736 1470-8736 |
DOI | 10.1042/CS20120661 |
Cover
Abstract | Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, however, contributes only in part to this protection. Therefore we investigated whether mildly elevated circulating UCB (unconjugated bilirubin) is associated with altered lipid metabolism. The study was performed on GS and age- and gender-matched healthy subjects (n=59 per group). Full lipoprotein profile, TAG (triacylglycerols), Apo (apolipoprotein)-A1, Apo-B, lipoprotein(a), the subfractions of LDL (low-density lipoprotein) and selected pro-inflammatory mediators were analysed. A hyperbilirubinaemic rodent model (Gunn rats, n=40) was investigated to further support the presented human data. GS subjects had significantly (P<0.05) improved lipid profile with reduced total cholesterol, LDL-C (LDL-cholesterol), TAG, low- and pro-atherogenic LDL subfractions (LDL-1+LDL-2), Apo-B, Apo-B/Apo-A1 ratio and lower IL-6 (interleukin 6) and SAA (serum amyloid A) concentrations (P=0.094). When the control and GS groups were subdivided into younger and older cohorts, older GS subjects demonstrated reduced lipid variables (total cholesterol and LDL-C, TAG and LDL-C subfractions, Apo-B/Apo-A1 ratio; P<0.05; Apo-B: P<0.1) compared with controls. These data were supported by lipid analyses in the rodent model showing that Gunn rat serum had lower total cholesterol (2.29±0.38 compared with 1.27±0.72 mM; P<0.001) and TAG (1.66±0.67 compared with 0.99±0.52 mM; P<0.001) concentrations compared with controls. These findings indicate that the altered lipid profile and the reduced pro-inflammatory status in hyperbilirubinaemic subjects, particularly in the older individuals, probably contribute additionally to the commonly accepted beneficial antioxidant effects of bilirubin in humans. |
---|---|
AbstractList | Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, however, contributes only in part to this protection. Therefore we investigated whether mildly elevated circulating UCB (unconjugated bilirubin) is associated with altered lipid metabolism. The study was performed on GS and age- and gender-matched healthy subjects (n=59 per group). Full lipoprotein profile, TAG (triacylglycerols), Apo (apolipoprotein)-A1, Apo-B, lipoprotein(a), the subfractions of LDL (low-density lipoprotein) and selected pro-inflammatory mediators were analysed. A hyperbilirubinaemic rodent model (Gunn rats, n=40) was investigated to further support the presented human data. GS subjects had significantly (P<0.05) improved lipid profile with reduced total cholesterol, LDL-C (LDL-cholesterol), TAG, low- and pro-atherogenic LDL subfractions (LDL-1+LDL-2), Apo-B, Apo-B/Apo-A1 ratio and lower IL-6 (interleukin 6) and SAA (serum amyloid A) concentrations (P=0.094). When the control and GS groups were subdivided into younger and older cohorts, older GS subjects demonstrated reduced lipid variables (total cholesterol and LDL-C, TAG and LDL-C subfractions, Apo-B/Apo-A1 ratio; P<0.05; Apo-B: P<0.1) compared with controls. These data were supported by lipid analyses in the rodent model showing that Gunn rat serum had lower total cholesterol (2.29±0.38 compared with 1.27±0.72 mM; P<0.001) and TAG (1.66±0.67 compared with 0.99±0.52 mM; P<0.001) concentrations compared with controls. These findings indicate that the altered lipid profile and the reduced pro-inflammatory status in hyperbilirubinaemic subjects, particularly in the older individuals, probably contribute additionally to the commonly accepted beneficial antioxidant effects of bilirubin in humans. Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, however, contributes only in part to this protection. Therefore we investigated whether mildly elevated circulating UCB (unconjugated bilirubin) is associated with altered lipid metabolism. The study was performed on GS and age- and gender-matched healthy subjects (n=59 per group). Full lipoprotein profile, TAG (triacylglycerols), Apo (apolipoprotein)-A1, Apo-B, lipoprotein(a), the subfractions of LDL (low-density lipoprotein) and selected pro-inflammatory mediators were analysed. A hyperbilirubinaemic rodent model (Gunn rats, n=40) was investigated to further support the presented human data. GS subjects had significantly (P<0.05) improved lipid profile with reduced total cholesterol, LDL-C (LDL-cholesterol), TAG, low- and pro-atherogenic LDL subfractions (LDL-1+LDL-2), Apo-B, Apo-B/Apo-A1 ratio and lower IL-6 (interleukin 6) and SAA (serum amyloid A) concentrations (P=0.094). When the control and GS groups were subdivided into younger and older cohorts, older GS subjects demonstrated reduced lipid variables (total cholesterol and LDL-C, TAG and LDL-C subfractions, Apo-B/Apo-A1 ratio; P<0.05; Apo-B: P<0.1) compared with controls. These data were supported by lipid analyses in the rodent model showing that Gunn rat serum had lower total cholesterol (2.29±0.38 compared with 1.27±0.72 mM; P<0.001) and TAG (1.66±0.67 compared with 0.99±0.52 mM; P<0.001) concentrations compared with controls. These findings indicate that the altered lipid profile and the reduced pro-inflammatory status in hyperbilirubinaemic subjects, particularly in the older individuals, probably contribute additionally to the commonly accepted beneficial antioxidant effects of bilirubin in humans. Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, however, contributes only in part to this protection. Therefore we investigated whether mildly elevated circulating UCB (unconjugated bilirubin) is associated with altered lipid metabolism. The study was performed on GS and age- and gender-matched healthy subjects (n=59 per group). Full lipoprotein profile, TAG (triacylglycerols), Apo (apolipoprotein)-A1, Apo-B, lipoprotein(a), the subfractions of LDL (low-density lipoprotein) and selected pro-inflammatory mediators were analysed. A hyperbilirubinaemic rodent model (Gunn rats, n=40) was investigated to further support the presented human data. GS subjects had significantly (P<0.05) improved lipid profile with reduced total cholesterol, LDL-C (LDL-cholesterol), TAG, low- and pro-atherogenic LDL subfractions (LDL-1+LDL-2), Apo-B, Apo-B/Apo-A1 ratio and lower IL-6 (interleukin 6) and SAA (serum amyloid A) concentrations (P=0.094). When the control and GS groups were subdivided into younger and older cohorts, older GS subjects demonstrated reduced lipid variables (total cholesterol and LDL-C, TAG and LDL-C subfractions, Apo-B/Apo-A1 ratio; P<0.05; Apo-B: P<0.1) compared with controls. These data were supported by lipid analyses in the rodent model showing that Gunn rat serum had lower total cholesterol (2.29±0.38 compared with 1.27±0.72 mM; P<0.001) and TAG (1.66±0.67 compared with 0.99±0.52 mM; P<0.001) concentrations compared with controls. These findings indicate that the altered lipid profile and the reduced pro-inflammatory status in hyperbilirubinaemic subjects, particularly in the older individuals, probably contribute additionally to the commonly accepted beneficial antioxidant effects of bilirubin in humans.Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's syndrome), which is characterized by a mildly elevated blood bilirubin concentration. The established antioxidant effect of bilirubin, however, contributes only in part to this protection. Therefore we investigated whether mildly elevated circulating UCB (unconjugated bilirubin) is associated with altered lipid metabolism. The study was performed on GS and age- and gender-matched healthy subjects (n=59 per group). Full lipoprotein profile, TAG (triacylglycerols), Apo (apolipoprotein)-A1, Apo-B, lipoprotein(a), the subfractions of LDL (low-density lipoprotein) and selected pro-inflammatory mediators were analysed. A hyperbilirubinaemic rodent model (Gunn rats, n=40) was investigated to further support the presented human data. GS subjects had significantly (P<0.05) improved lipid profile with reduced total cholesterol, LDL-C (LDL-cholesterol), TAG, low- and pro-atherogenic LDL subfractions (LDL-1+LDL-2), Apo-B, Apo-B/Apo-A1 ratio and lower IL-6 (interleukin 6) and SAA (serum amyloid A) concentrations (P=0.094). When the control and GS groups were subdivided into younger and older cohorts, older GS subjects demonstrated reduced lipid variables (total cholesterol and LDL-C, TAG and LDL-C subfractions, Apo-B/Apo-A1 ratio; P<0.05; Apo-B: P<0.1) compared with controls. These data were supported by lipid analyses in the rodent model showing that Gunn rat serum had lower total cholesterol (2.29±0.38 compared with 1.27±0.72 mM; P<0.001) and TAG (1.66±0.67 compared with 0.99±0.52 mM; P<0.001) concentrations compared with controls. These findings indicate that the altered lipid profile and the reduced pro-inflammatory status in hyperbilirubinaemic subjects, particularly in the older individuals, probably contribute additionally to the commonly accepted beneficial antioxidant effects of bilirubin in humans. |
Author | Vitek, Libor Wagner, Oswald Wagner, Karl-Heinz Bulmer, Andrew C. Wolzt, Michael Wallner, Marlies Marculescu, Rodrig Doberer, Daniel |
Author_xml | – sequence: 1 givenname: Marlies surname: Wallner fullname: Wallner, Marlies organization: Department of Nutritional Sciences, Emerging Field ‘Oxidative Stress and DNA Stability’ and Research Platform ‘Active Ageing’, University of Vienna, Vienna, Austria – sequence: 2 givenname: Rodrig surname: Marculescu fullname: Marculescu, Rodrig organization: Clinical Institute of Laboratory Medicine, Medical University of Vienna, Vienna, Austria – sequence: 3 givenname: Daniel surname: Doberer fullname: Doberer, Daniel organization: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria – sequence: 4 givenname: Michael surname: Wolzt fullname: Wolzt, Michael organization: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria – sequence: 5 givenname: Oswald surname: Wagner fullname: Wagner, Oswald organization: Clinical Institute of Laboratory Medicine, Medical University of Vienna, Vienna, Austria – sequence: 6 givenname: Libor surname: Vitek fullname: Vitek, Libor organization: 4th Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Medicine, Charles University in Prague, Prague, Czech Republic – sequence: 7 givenname: Andrew C. surname: Bulmer fullname: Bulmer, Andrew C. organization: Heart Foundation Research Centre, Griffith Health Institute, Griffith University, Southport, Australia – sequence: 8 givenname: Karl-Heinz surname: Wagner fullname: Wagner, Karl-Heinz organization: Department of Nutritional Sciences, Emerging Field ‘Oxidative Stress and DNA Stability’ and Research Platform ‘Active Ageing’, University of Vienna, Vienna, Austria, Heart Foundation Research Centre, Griffith Health Institute, Griffith University, Southport, Australia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23566065$$D View this record in MEDLINE/PubMed |
BookMark | eNptkV1rFTEQhoNU7Gn1xh8guVOE1cnnbi_loFUotFC9XmaTORLNbo5JttB_0J9t-kVBZC4yF8_7zuSdI3awpIUYey3ggwAtP24vJQgJ1opnbCN0D93QK3vANiC06oyU4pAdlfILQKpWL9ihVMZasGbDbi5yquRqSAvf5TRz_EldpoiVPA-Ly4SFWsNj2AfPp5BmzL8pF47LLbCLOM94J3dpqTlMa6XCa-IOsw_pCotbI2a-f5rT3E5DnCjXt4WX68W3ufSSPd9hLPTq4T1mP758_r792p2dn37bfjrrnDKqdnYAOhncJDRpgZPR3gzgUaD3vXHgqaVgB-EU9aQJZI8gTzyZQQ89wYDqmL27920L_Vmp1HEOxVGMuFBayyiUERYGoWVD3zyg6zSTH_c5tM9fj4_pNQDuAZdTKZl2owv1LoyaMcRRwHh7oPHpQE3y_h_Jo-t_4L8JiZIg |
CitedBy_id | crossref_primary_10_1186_1742_4933_11_11 crossref_primary_10_3390_nu7021352 crossref_primary_10_1158_1940_6207_CAPR_13_0125 crossref_primary_10_1038_s41598_017_00933_y crossref_primary_10_1016_j_molmed_2023_01_007 crossref_primary_10_1042_CS20140566 crossref_primary_10_1038_srep15482 crossref_primary_10_1016_j_trre_2018_06_003 crossref_primary_10_1016_j_metabol_2021_154913 crossref_primary_10_1152_ajprenal_00039_2014 crossref_primary_10_1186_s12916_020_01703_w crossref_primary_10_1186_s12933_022_01484_x crossref_primary_10_3389_fphar_2020_594574 crossref_primary_10_1186_s12944_023_01979_w crossref_primary_10_1055_a_2237_8863 crossref_primary_10_3389_fphar_2020_636533 crossref_primary_10_1097_MD_0000000000017544 crossref_primary_10_1016_j_etap_2023_104321 crossref_primary_10_1038_srep09886 crossref_primary_10_1152_ajpendo_00405_2020 crossref_primary_10_1016_j_clinbiochem_2014_08_008 crossref_primary_10_1016_j_freeradbiomed_2015_08_020 crossref_primary_10_1016_j_atherosclerosis_2014_12_042 crossref_primary_10_1016_j_bj_2019_12_004 crossref_primary_10_3390_cancers15184584 crossref_primary_10_1016_j_cca_2016_12_020 crossref_primary_10_1042_CS20242825 crossref_primary_10_1515_anre_2017_0024 crossref_primary_10_3109_00365513_2015_1031691 crossref_primary_10_1186_1475_2840_12_166 crossref_primary_10_1016_j_lfs_2020_118032 crossref_primary_10_3389_fendo_2021_792795 crossref_primary_10_1016_j_tem_2018_01_002 crossref_primary_10_3390_antiox10091474 crossref_primary_10_3390_nu8060338 crossref_primary_10_3390_biom13020252 crossref_primary_10_1152_ajpgi_00026_2018 crossref_primary_10_1371_journal_pone_0079073 crossref_primary_10_1080_10408363_2018_1428526 crossref_primary_10_1177_0003319716660240 crossref_primary_10_1152_ajpheart_00417_2017 crossref_primary_10_1038_s41537_024_00473_1 crossref_primary_10_1016_j_metabol_2024_156081 crossref_primary_10_3389_fcvm_2022_822626 crossref_primary_10_3892_etm_2018_6184 crossref_primary_10_1161_JAHA_117_005520 crossref_primary_10_1016_j_isci_2024_110234 crossref_primary_10_1152_physiolgenomics_00028_2019 crossref_primary_10_1016_j_atherosclerosis_2014_12_053 crossref_primary_10_1097_j_pbj_0000000000000275 crossref_primary_10_1111_eci_12120 crossref_primary_10_1080_09537104_2017_1280146 crossref_primary_10_1038_srep30051 crossref_primary_10_1016_j_clinbiochem_2015_06_016 crossref_primary_10_1155_2014_175286 crossref_primary_10_1007_s10072_020_04268_x crossref_primary_10_1038_srep22300 crossref_primary_10_3390_medicina59101837 crossref_primary_10_1161_HYPERTENSIONAHA_118_11130 crossref_primary_10_1016_j_atherosclerosis_2015_11_008 crossref_primary_10_1089_ars_2013_5667 crossref_primary_10_2174_1567202616666190412153735 crossref_primary_10_3389_fcvm_2022_967097 crossref_primary_10_3389_fphar_2021_646953 crossref_primary_10_1186_1472_6823_13_39 crossref_primary_10_2478_jomb_2014_0058 crossref_primary_10_1186_s12872_022_02899_w crossref_primary_10_1016_j_atherosclerosis_2014_05_927 crossref_primary_10_3389_fcimb_2021_701109 crossref_primary_10_3390_jcm10132812 crossref_primary_10_1113_JP282395 crossref_primary_10_1152_ajpendo_00396_2016 crossref_primary_10_1007_s11906_019_0994_z crossref_primary_10_1016_j_pharmthera_2021_107975 |
Cites_doi | 10.1161/01.CIR.0000115516.54550.B1 10.1371/journal.pone.0018582 10.1194/jlr.R200004-JLR200 10.2215/CJN.06130710 10.1111/j.1365-2796.2006.01643.x 10.1089/jwh.2010.2453 10.1016/j.jacl.2011.02.001 10.1038/nature05487 10.1093/clinchem/47.2.266 10.1016/j.freeradbiomed.2012.03.002 10.1016/j.numecd.2011.03.001 10.1515/cclm.2011.662 10.1165/rcmb.2009-0170TR 10.1371/journal.pmed.0030287 10.1111/j.1478-3231.2008.01821.x 10.1002/hep.1840400412 10.1016/j.atherosclerosis.2007.11.022 10.1016/j.clinbiochem.2010.12.003 10.1001/jama.286.3.327 10.5551/jat.6346 10.1016/j.metabol.2009.04.003 10.1111/j.1582-4934.2010.01098.x 10.1056/NEJM199511023331802 10.1124/dmd.110.035030 10.1016/0891-5849(95)00032-S 10.1001/jama.2011.124 10.1002/ajmg.10209 10.1001/jama.2009.1619 10.1093/clinchem/40.1.18 10.1023/A:1013794407325 10.1016/j.plipres.2012.11.001 10.1111/j.1365-2796.2008.02016.x 10.1177/15353702-0322805-29 10.1161/CIRCULATIONAHA.104.528802 10.1097/MOL.0b013e3283488c39 10.1016/j.numecd.2007.02.010 10.1111/j.1440-1746.2006.04564.x |
ContentType | Journal Article |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1042/CS20120661 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1470-8736 |
EndPage | 264 |
ExternalDocumentID | 23566065 10_1042_CS20120661 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 0R~ 0VX 29B 2WC 4.4 5GY 5RE 5VS 6J9 AAYXX ABCQX ABJNI ACGFO ACGFS ADBBV AEGXH AENEX AIAGR AIZAD ALMA_UNASSIGNED_HOLDINGS BAWUL CITATION CS3 DU5 E3Z EBD EBS EJD EMOBN F5P GX1 H13 HZ~ L7B MV1 NTEUP O9- P2P P6G RHI RPO SV3 TR2 WH7 .55 .GJ 3O- 53G AABGO AAHRG AFFNX AFFVI AI. CGR CUY CVF ECM EIF MVM NPM OHT VH1 X7M ZGI ZXP 7X8 |
ID | FETCH-LOGICAL-c353t-680e98cb14e41ab54d580da1add75c0de661681c3e7e4e027a029de58487e08a3 |
ISSN | 0143-5221 1470-8736 |
IngestDate | Fri Jul 11 12:02:02 EDT 2025 Thu Jan 02 22:11:05 EST 2025 Tue Jul 01 03:56:50 EDT 2025 Thu Apr 24 22:54:46 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c353t-680e98cb14e41ab54d580da1add75c0de661681c3e7e4e027a029de58487e08a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 23566065 |
PQID | 1351608142 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_1351608142 pubmed_primary_23566065 crossref_citationtrail_10_1042_CS20120661 crossref_primary_10_1042_CS20120661 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2013-09-01 |
PublicationDateYYYYMMDD | 2013-09-01 |
PublicationDate_xml | – month: 09 year: 2013 text: 2013-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Clinical science (1979) |
PublicationTitleAlternate | Clin Sci (Lond) |
PublicationYear | 2013 |
References | Chowdhury (2021113010282006400_B20) 1993; 37 King (2021113010282006400_B25) 2011; 22 Otvos (2021113010282006400_B19) 2011; 5 Vitek (2021113010282006400_B33) 2007; 22 Chen (2021113010282006400_B5) 2011; 6 Muchova (2021113010282006400_B10) 2011; 15 Walldius (2021113010282006400_B39) 2006; 259 Dennery (2021113010282006400_B11) 1995; 19 Bosma (2021113010282006400_B6) 1995; 333 Pradhan (2021113010282006400_B23) 2001; 286 Horsfall (2021113010282006400_B4) 2011; 305 Walldius (2021113010282006400_B40) 2007; 17 Zucker (2021113010282006400_B3) 2004; 40 Tapan (2021113010282006400_B17) 2011; 44 Yang (2021113010282006400_B24) 2006; 3 Hoefner (2021113010282006400_B26) 2001; 47 Novotny (2021113010282006400_B1) 2003; 228 Zhou (2021113010282006400_B35) 2011; 39 Bulmer (2021113010282006400_B9) 2008; 199 Choi (2021113010282006400_B28) 2013; 23 Johnson (2021113010282006400_B41) 2004; 109 Elmadfa (2021113010282006400_B27) 2009 Stocker (2021113010282006400_B8) 2004; 6 Emerging Risk Factors Collaboration (2021113010282006400_B21) 2009; 302 Andersson (2021113010282006400_B31) 2009; 58 Fertrin (2021113010282006400_B7) 2002; 108 Boon (2021113010282006400_B13) 2012; 52 Ocadlik (2021113010282006400_B18) 2011; 32 Holme (2021113010282006400_B38) 2009; 265 Temme (2021113010282006400_B2) 2001; 12 Ryter (2021113010282006400_B16) 2009; 41 Hwang (2021113010282006400_B42) 2011; 49 Kwon (2021113010282006400_B29) 2011; 20 Berneis (2021113010282006400_B36) 2002; 43 Bulmer (2021113010282006400_B30) 2012; 52 Lippi (2021113010282006400_B34) 2009; 29 Van Gaal (2021113010282006400_B22) 2006; 444 Leitzmann (2021113010282006400_B32) 2011; 6 Smith (2021113010282006400_B37) 2011; 58 Schwertner (2021113010282006400_B12) 1994; 40 Yoshino (2021113010282006400_B14) 2011; 18 Ollinger (2021113010282006400_B15) 2005; 112 |
References_xml | – volume: 37 start-page: 149 year: 1993 ident: 2021113010282006400_B20 article-title: Gunn rat: a model for inherited deficiency of bilirubin glucuronidation publication-title: Adv. Vet. Sci. Comp. Med. – volume: 109 start-page: 726 year: 2004 ident: 2021113010282006400_B41 article-title: Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE) publication-title: Circulation doi: 10.1161/01.CIR.0000115516.54550.B1 – volume-title: Austrian Nutrition Report 2008 year: 2009 ident: 2021113010282006400_B27 – volume: 6 start-page: e18582 year: 2011 ident: 2021113010282006400_B32 article-title: Waist circumference as compared with body-mass index in predicting mortality from specific causes publication-title: PLoS ONE doi: 10.1371/journal.pone.0018582 – volume: 43 start-page: 1363 year: 2002 ident: 2021113010282006400_B36 article-title: Metabolic origins and clinical significance of LDL heterogeneity publication-title: J. Lipid Res. doi: 10.1194/jlr.R200004-JLR200 – volume: 6 start-page: 567 year: 2011 ident: 2021113010282006400_B5 article-title: Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients publication-title: Clin. J. Am. Soc. Nephrol. doi: 10.2215/CJN.06130710 – volume: 259 start-page: 493 year: 2006 ident: 2021113010282006400_B39 article-title: The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence publication-title: J. Intern. Med. doi: 10.1111/j.1365-2796.2006.01643.x – volume: 20 start-page: 963 year: 2011 ident: 2021113010282006400_B29 article-title: Inverse association between total bilirubin and metabolic syndrome in rural Korean women publication-title: J. Womens Health doi: 10.1089/jwh.2010.2453 – volume: 5 start-page: 105 year: 2011 ident: 2021113010282006400_B19 article-title: Clinical implications of discordance between low-density lipoprotein cholesterol and particle number publication-title: J. Clin. Lipidol. doi: 10.1016/j.jacl.2011.02.001 – volume: 444 start-page: 875 year: 2006 ident: 2021113010282006400_B22 article-title: Mechanisms linking obesity with cardiovascular disease publication-title: Nature doi: 10.1038/nature05487 – volume: 47 start-page: 266 year: 2001 ident: 2021113010282006400_B26 article-title: Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System publication-title: Clin. Chem. doi: 10.1093/clinchem/47.2.266 – volume: 52 start-page: 2120 year: 2012 ident: 2021113010282006400_B13 article-title: Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome publication-title: Free Radical Biol. Med. doi: 10.1016/j.freeradbiomed.2012.03.002 – volume: 23 start-page: 31 year: 2013 ident: 2021113010282006400_B28 article-title: Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults publication-title: Nutr. Metab. Cardiovasc. Dis. doi: 10.1016/j.numecd.2011.03.001 – volume: 49 start-page: 1823 year: 2011 ident: 2021113010282006400_B42 article-title: Relationship between bilirubin and C-reactive protein publication-title: Clin. Chem. Lab. Med. doi: 10.1515/cclm.2011.662 – volume: 41 start-page: 251 year: 2009 ident: 2021113010282006400_B16 article-title: Heme oxygenase-1/carbon monoxide: from metabolism to molecular therapy publication-title: Am. J. Respir. Cell Mol. Biol. doi: 10.1165/rcmb.2009-0170TR – volume: 3 start-page: e287 year: 2006 ident: 2021113010282006400_B24 article-title: Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications publication-title: PLoS Med. doi: 10.1371/journal.pmed.0030287 – volume: 29 start-page: 315 year: 2009 ident: 2021113010282006400_B34 article-title: Bilirubin concentration and cardiovascular risk profile publication-title: Liver Int. doi: 10.1111/j.1478-3231.2008.01821.x – volume: 58 start-page: 2432 year: 2011 ident: 2021113010282006400_B37 article-title: AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association publication-title: Circulation – volume: 40 start-page: 827 year: 2004 ident: 2021113010282006400_B3 article-title: Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer publication-title: Hepatology doi: 10.1002/hep.1840400412 – volume: 199 start-page: 390 year: 2008 ident: 2021113010282006400_B9 article-title: Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2007.11.022 – volume: 44 start-page: 300 year: 2011 ident: 2021113010282006400_B17 article-title: Decreased small dense LDL levels in Gilbert's syndrome publication-title: Clin. Biochem. doi: 10.1016/j.clinbiochem.2010.12.003 – volume: 286 start-page: 327 year: 2001 ident: 2021113010282006400_B23 article-title: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus publication-title: JAMA, J. Am. Med. Assoc. doi: 10.1001/jama.286.3.327 – volume: 18 start-page: 403 year: 2011 ident: 2021113010282006400_B14 article-title: Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients publication-title: J. Atheroscler. Thromb. doi: 10.5551/jat.6346 – volume: 58 start-page: 1109 year: 2009 ident: 2021113010282006400_B31 article-title: Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial publication-title: Metab., Clin. Exp. doi: 10.1016/j.metabol.2009.04.003 – volume: 15 start-page: 1156 year: 2011 ident: 2021113010282006400_B10 article-title: Bile acids decrease intracellular bilirubin levels in the cholestatic liver: implications for bile acid-mediated oxidative stress publication-title: J. Cell. Mol. Med. doi: 10.1111/j.1582-4934.2010.01098.x – volume: 333 start-page: 1171 year: 1995 ident: 2021113010282006400_B6 article-title: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199511023331802 – volume: 39 start-page: 322 year: 2011 ident: 2021113010282006400_B35 article-title: Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors publication-title: Drug Metab. Dispos. doi: 10.1124/dmd.110.035030 – volume: 19 start-page: 395 year: 1995 ident: 2021113010282006400_B11 article-title: Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia publication-title: Free Radical Biol. Med. doi: 10.1016/0891-5849(95)00032-S – volume: 305 start-page: 691 year: 2011 ident: 2021113010282006400_B4 article-title: Serum bilirubin and risk of respiratory disease and death publication-title: JAMA, J. Am. Med. Assoc. doi: 10.1001/jama.2011.124 – volume: 108 start-page: 117 year: 2002 ident: 2021113010282006400_B7 article-title: Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil publication-title: Am. J. Med. Genet. doi: 10.1002/ajmg.10209 – volume: 302 start-page: 1993 year: 2009 ident: 2021113010282006400_B21 article-title: Major lipids, apolipoproteins, and risk of vascular disease publication-title: JAMA, J. Am. Med. Assoc. doi: 10.1001/jama.2009.1619 – volume: 40 start-page: 18 year: 1994 ident: 2021113010282006400_B12 article-title: Association of low serum concentration of bilirubin with increased risk of coronary artery disease publication-title: Clin. Chem. doi: 10.1093/clinchem/40.1.18 – volume: 12 start-page: 887 year: 2001 ident: 2021113010282006400_B2 article-title: Serum bilirubin and 10-year mortality risk in a Belgian population publication-title: Cancer Causes Control doi: 10.1023/A:1013794407325 – volume: 32 start-page: 360 year: 2011 ident: 2021113010282006400_B18 article-title: Relationship between unconjugated hyperbilirubinemia and lipoprotein spectrum publication-title: Neuro. Endocrinol. Lett. – volume: 52 start-page: 193 year: 2012 ident: 2021113010282006400_B30 article-title: Bilirubin and beyond: a review of lipid status in Gilbert's syndrome and its relevance to cardiovascular disease protection publication-title: Prog. Lipid Res. doi: 10.1016/j.plipres.2012.11.001 – volume: 265 start-page: 275 year: 2009 ident: 2021113010282006400_B38 article-title: Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS) publication-title: J. Intern. Med. doi: 10.1111/j.1365-2796.2008.02016.x – volume: 228 start-page: 568 year: 2003 ident: 2021113010282006400_B1 article-title: Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies publication-title: Exp. Biol. Med. doi: 10.1177/15353702-0322805-29 – volume: 112 start-page: 1030 year: 2005 ident: 2021113010282006400_B15 article-title: Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.104.528802 – volume: 22 start-page: 302 year: 2011 ident: 2021113010282006400_B25 article-title: Serum amyloid A in atherosclerosis publication-title: Curr. Opin. Lipidol. doi: 10.1097/MOL.0b013e3283488c39 – volume: 17 start-page: 565 year: 2007 ident: 2021113010282006400_B40 article-title: Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A – new risk factors and targets for therapy publication-title: Nutr. Metab. Cardiovasc. Dis. doi: 10.1016/j.numecd.2007.02.010 – volume: 6 start-page: 841 year: 2004 ident: 2021113010282006400_B8 article-title: Antioxidant activities of bile pigments publication-title: Antioxid. Redox Signaling – volume: 22 start-page: 841 year: 2007 ident: 2021113010282006400_B33 article-title: Urinary excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome publication-title: J. Gastroenterol. Hepatol. doi: 10.1111/j.1440-1746.2006.04564.x |
SSID | ssj0023232 |
Score | 2.3831353 |
Snippet | Recent epidemiological and clinical data show protection from CVD (cardiovascular disease), all-cause mortality and cancer in subjects with GS (Gilbert's... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 257 |
SubjectTerms | Adiposity Adult Aging - blood Animals Bilirubin - blood Biomarkers - blood Cardiovascular Diseases - blood Case-Control Studies Disease Models, Animal Female Gilbert Disease - blood Humans Inflammation - blood Lipid Metabolism Lipoproteins - blood Male Middle Aged Rats Rats, Gunn Young Adult |
Title | Protection from age-related increase in lipid biomarkers and inflammation contributes to cardiovascular protection in Gilbert's syndrome |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23566065 https://www.proquest.com/docview/1351608142 |
Volume | 125 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIiEuiDddHjICCXEIJM7DzhGhXVZod0GilXqLHNuLIpWmatPL_oI98ZuZsZ0XFGnhEqVRYleZT9NvpjPfEPKaR1JzI7IAAto4SHhoAplhDv4iKxnTZcqVVfs8z07myedFuphMfg6qlnZN-U5d7u0r-R-rwjWwK3bJ_oNlu0XhApyDfeEIFobjtWz81Yks2GpBbBMB3xDY5hSDikrIB7dWE2RZrSsgmlX9A4txNlsvuXQBaHCdi65iHUdfOcUHNa5SXff7wGqfKtTFamymf6_gwajZUlkSG-U8HyQdMH3vO23O5GY5KGSEj7CngY1d3bfeVN87so1V4O4p1xnfLVcvL5vfmwB8KgPHSuRtKsN5X8AKuOfYa2Pvuda6bNcs7bGZDh2wk7v-44cBfBMKDn9j2CycOf33sfr2-ZfieH56WsyOFrMb5CbjwMWweXzRlQwB-bQD77qv1MrdJux9v_KY4PwlarHsZXaX3PFhB_3gMHSPTMzqPrl15gsrHpCrHkoUoUQHUKItlOCEWijRHkoUoESHUKIDKNGmpmMo0R5KuJqH0pstbYH0kMyPj2YfTwI_pCNQcRo3QSZCkwtVRolJIlmmiU5FqCW4AM1TFWoDryQTkYoNN4kJGZchy7UB3iu4CYWMH5GDVb0yTwjNSiF1HhohcSgARC6CKSYggsAYQ3M-JW_bN1sor2CPg1SWha2kSFjRW2FKXnX3rp1uy967XrYGKsCt4n9lcmXq3bbAwZUZ0OWETcljZ7luHRZDDATU_fAaTz8lt3ukPyMHzWZnngONbcoXFlu_ALNsofg |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protection+from+age-related+increase+in+lipid+biomarkers+and+inflammation+contributes+to+cardiovascular+protection+in+Gilbert%27s+syndrome&rft.jtitle=Clinical+science+%281979%29&rft.au=Wallner%2C+Marlies&rft.au=Marculescu%2C+Rodrig&rft.au=Doberer%2C+Daniel&rft.au=Wolzt%2C+Michael&rft.date=2013-09-01&rft.issn=1470-8736&rft.eissn=1470-8736&rft.volume=125&rft.issue=5&rft.spage=257&rft_id=info:doi/10.1042%2FCS20120661&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0143-5221&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0143-5221&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0143-5221&client=summon |